Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065096 | 0.88 | CHRM1 (0.50) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL19128406 | 0.87 | KMT2A (0.43) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL9978637 | 0.87 | CHRM1 (0.49) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL16937247 | 0.87 | CHRM1 (0.61) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL19128179 | 0.86 | CHRM1 (0.50) | CHRM1KCNH2ALDH1A1 | |
| SCHEMBL1437099 | 0.85 | ABL1 (0.46) | CHRM1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL2337391 | 0.80 | ALDH1A1 (0.45) | KMT2AKDM4EMAPTALDH1A1GAA | |
| SCHEMBL6911869 | 0.80 | CHRM1 (0.44) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL9931087 | 0.80 | CHRM1 (0.44) | CHRM1KMT2AKDM4ELMNAMAPK1 | |
| SCHEMBL14740140 | 0.79 | CHRM1 (0.49) | CHRM1KMT2AKDM4EKCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915812-A1 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | Merck Sharp & Dohme Corp. (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2473048-B1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025851-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, OPRL1 | CHRM1 1/4885KMT2A 1146/4885KDM4E 841/4885 |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885KMT2A 997/4885KDM4E 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.